	01A				
Form PTO-14 (REV. 8-83)	V A 355	artment of Commerce Trademark Office	Atty. Docket: 0264724-0007	In re App 09/193,89	lication No. 2
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		TION	Applicant: Fogel		
		Filing Date: November 18, 1998	Group:	1614	
		U. S. PATENT DOCU	MENTS		
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date ,	Class	Subclass
Lun	4,122,193	Scherm et al.	October 24, 1978		
	4,233,229	Chakrabarti	November 11, 1980	IECH (Д
	4,355,043	Durlach	October 19, 1982	ĖN	1 C
	5,061,703	Bormann et al.	October 29, 1991	Ξ.	
	5,262,162	Bormann et al.	November 16, 1993	1600/290	
	5,382,601	Nürnberg et al.	January 17, 1995	8	
·	5,455,279	Lipton	October 3, 1995		
	5,602,150	Lidsky	February 11, 1997		
Jin	5,614,560	Lipton	March 25, 1997		
	FC	PREIGN PATENT DOC	CUMENTS		
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
				•	
					ر
Examiner's Initials	(In	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Tru	Alexander, et al., "S Clinical Phenomena	Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment", Brit. F. Psychiat. 133: 143-49, 1978.			
1-	Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J. Psychiatry 145:4, April, 1988.				

1.

	<u> </u>		·	
Form PTO-144 (REV. 8-83)	Department of Commerce	Atty. Decket: 0264724-0007	In re Application No. 09/193,892	
SUPPLEM	ENTAGENFORMATION OSURE STATEMENT	Applicant: Fogel	CT 03	
	everal sheets if necessary)	Filing Date: November 18, 1998	Group: 162290	
Inv	Andrew, "Clinical Relationship of Extrapyrami Can. J. Psych., 39:576-580, 1994.	dal Symptoms and Tar	dive Dyskinesia",	
	Andreassen, et al., "Tardive Dyskinesia: Behavorial Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994			
	Andreassen, et al., "Inhibition by Memantine of the Development of Persistant Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats", British Journal of Pharmacology 119: 751-757, 1996.			
	Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin", Can J. Ophthalmol, 22:1, 1987.			
	Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:4, August, 1983			
	Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms", Can. J. Psych., 39:74-84, 1994.			
	Boumans et al., "Is the Social Acceptability of Dyskinesia?", Schizo Bull, 20:339-344, 1994.	Psychiatric Patients D	ecreased by Orofacial	
	Britton, et al., "Dextromethorphan Protects Ag But Not Permanent, Focal Ischemia in Rats" L			
	Büchel et al., "Oral Tardive Dyskinesia: Valida Image Processing", Psychopharmacology-Berl,		Device Using Digital	
	Casey, D. "Pharmacology of Blepharospasm-O Neurology, 30:690-695, July, 1980.	romandibular Dystonia	Syndrome",	
	Cassady, et al., "Neuroleptic Induced Moveme Cambridge University Press, 1997, pp454-469.		dge, England:	
	Chabenat, et al., "Physicochemical, Pharmaco GABAerigic Compound, Calcium Acetylhomot Pharmacol, 10:311-7, 1988 May.	_	<u> </u>	
	Chakos et al., "Incidence and Correlates of Tal Schizophrenia", Arch Gen Psychiatry, 53:313-		st Episode of	
·	Chappell, et al., "Future Therapies of Tourette America, 15:2, May, 1997.	Syndrome", Neurolog	gic Clinics of North	
In	Chen, et al., "Focal Dystonia and Repetitive M. Related Research", 351: 102-106.	Iotion Disorders", Clir	nical Orthopaedics and	

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atry. Bocket: 0264724-0007	In re Application No. 7
11	ENTAL INFORMATION OSURE STATEMENT	Applicant: Fogel FR 160	
•	veral sheets if necessary)	Filing Date: November 18, 1998	Group: 16
Ju	Dabiri, et al., "Effectiveness of Vitamin E for Dyskinesia", Am J. Psychiatry 151:6, June 19	_	rm Tardive
	Decker et al., "Amantadine Hydrochloride Trea New England J. Med, 285:860, 1971.	atment of Tardive Dys	kinesia", October 7,
	Delfs et al., "Expression of Glutamic Acid Dec in an Animal Model of Tardive Dyskinesia", E		
De Mattos, et al., "Distonias Aspectos Clinicose E Terapeuticos EM 64 Pacientes", Neuropsiquiatr, 54:30-36, 1996.			64 Pacientes", Arq.
Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in V Arzneimittelforschung, 45:1-5, 1995.			pocampus in Vitro",
	Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25 42, 1997.		
Egan M.F., et al., "Treatment of Tardive Dyskinesia" Schizophr Bull, 23(4):583-609 1			1, 23(4):583-609 1997
·	Elston, J. "The Management of Blepharospasm 1992.	and Hemifacial Spasn	1", J. Neurol 239:5-8,
	Ema, et al., "Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium", Alcohol, 15:95-103, 1998.		
	Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Exci Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 1921, 1991.		
	Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options", Tennessee Medicine, 18-20, January, 1997.		
	Fariello, R.G. et al., "Homotaurine (3 Aminop The Convulsant and Cytotoxic Effect of System Neurology, 32:241-5, March, 1982.	•	•
	Galardi, et al., "Basal Ganglia and Thalamo-Co Spasmodic Torticollis", Acta Neurol Scand 94:		m in Patients with
	Greensmith, et al., "Magnesium Ions Reduce M Exposure to N-Methyl-D-Aspartate In The Deve		owing Nerve Injury or
	Gao et al., "Tiagabine Inhibits Haloperidol-Indi Transmission, 95:63-69, 1994.	uced Oral Dyskinesias	in Rats", J. Neural

Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511, -1995.

Form PTO-1449 (REV. 8-83)	
SUPPLEM DISCL	
(Use se	veral s
· TML	Gulle of the

U.S. Department of Commerce

Patent and Trademark Off

L INFORMATION E STATEMENT

In re Application No. 09/193,892 Any. Docket: 0264724-0007 Applicant: Fogel Group: 16 Filing Date: November 18, 1998

hoose if nocossary)

(Use s	everal sheets if necessary) Appendix November 18, 1998		
. Tur	Gullestad, et al., "Magnesium Status in Healthy Free-Living Elderly Norwegians", Journal of the American College of Nutrition, 13:1,45-50.		
1	Hallett, M. "The Neurophysiology of Dystonia", Arch Neurol, 55: May, 1998		
	Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-398, 1996.		
	Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm", AFP, 43(6): 2113-2120, June, 1991.		
	Imamura et al., "Improved Preseveration with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.		
	Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, March, 1990.		
	Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982.		
	Jankovic, J. "Blepharospasm and Orofacial - Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.		
	Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.		
	Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur J. Pharmacol, 219:451-454, 1992.		
	Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994.		
	Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996. Krielglstein, et al., "Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage		
	Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", The Japanese Journal of Psychiatry" 43: 627-631, 1989.		
	Kurlan, R. "Treatment of Tics", Neurologic Clinics of North America, 15:2, 403-409, May, 1997.		
	Lam et al., "Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994.		
Inc	Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.		

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0264724-0007	In re Applicat No. 09/193,892		
	IENTAL INFORMATION LOSURE STATEMENT SEP 2 8 2001	Applicant: Fogel	0.3 21 VIER 16		
	(Use several sheets if necessary) Filing Date: November 18, 1998 Group: 16175				
· Inc	Leckman, et al., "Tic Disorders", The Psychia December, 1997.	tric Clinics of North A	merica, 20:4 839-861,		
·	Lichter, et al., "Predictors of Clonidine Respondences", Journal of Child Neurology 11:93		me: Implications and		
	Lipski, et al., "A Study of Nutritional Deficits Agening 22:244-255, 1993.	of Long-Stay Geriatric	Patients, Age and		
	Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.				
	Lombardini, John B. "Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations"				
	Martin, et al., "Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects", J. Trace Elem. Electrolytes Health Dis.,5:203-211, 1991.				
	Mauriello, et al., "Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years", Br. J. Ophthamaol, 80(12):1073-1076, December, 1996				
	Mauriello, et al., "Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years", Clinical Neurology and Neurosurgery, 98: 213-216, August 1996.				
	Meshul, et al., "Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol", Psychopharmacology 125:238-247, 1996				
	Micheli, et al., "Continuous Dopaminergic Stimulation in Cranial Dystonia", Clinical Neuropharmacology, 11:3, 241-249.				
	Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", Pharmacopsychiatry, 28:113-124, 1995.				
·	Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", J. Neuropsych Clin. Neurosci, 7:457-465, 1995.				
·	Panula-Lehto E. et al., "Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striataldopamine Metabolism." Naunyn Schmiedebergs Arch Pharmacol, 346:57-62, July, 1992				
	Perlmutter, et al., "Decreased [18F] Spiperone Binding in Putamen Idiopathic Focal Dystonia", The Journal of Neuroscience, 17:843-850, 1997.				
41	Plocéniak, "Bruxisme et magnesium, mon expe	rience clinique depuis	1980" Communications		

			Ti		
Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0264724-0007	In re Application No.	BEC	
	ENTAL INFORMATION OSURE STATEMENT	Applicant: Fogel	0-3-20 ER 160	E	
(Use several sheets if necessary) SEP 2 8 2007 Filing Date: November 18, 1998 Group: 1618					
. Jr	Raja, "The Treatment of Tardive Dyskinesia", 47: 1996.	Abstract, Schweiz Arc	h Neurol Psychaitr,		
·	Ransmayr, et al., "Pharmacological Study in M Blepharospasm", Clinical Neuropharmacology"		Predominant		
	Rouhani, S. et al., "Effects of Muscimol or Ho dependent rats during Withdrawal." Pharmacol			-	
	Sachdev, "Blinking-blepharospasm after long-te Journal of Australia, 150:341-343, March 20, 1		ent", The Medical		
	Sachdev et al., "Negative Symptoms, Cognitive Dyskinesia", Acta Psychiatr Scand, 93:451-459		Akathisia and Tardi	re	
	Sanberg, et al., "Nicotine for the Treatment of Tourette's Syndrome", Pharmacol. Ther. Vol. 74, 21-25, 1997.				
	Sandyk, "Blepharospasm - Successful Treatment with Baclofen and Sodium Valproate", SA Medical Journal, 64:3 December, 1993.				
	Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, Vol. 336, No. 17, pp. 1216-1247, April 24, 1997.				
	Scahill, et al., "Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study," Journal of Child and Adolescent Psychopharmacology, 7:75-85, 1997.				
	Schulz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", Neuroscience, 71:1043-1048, 1996.				
	Shane, et al., "Magnesium Deficiency in Alcohol Addiction and Withdrawal", Magnes Trace Elem, 92:263-268, 1991.				
	Silver et al., "No Difference in the Effect of Biperiden and Amantadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo- Controlled Study in Medicated Chronic Schizophrenic Patients", Abstract, J. Clin. Psychiatry, 56:167-170, 1995.				
	Silver, et al., "Case Study: Long-Term Potential Nicotine in Tourette's Syndrome, J. Am. Chil. 1996				
	Stoessl, "Effects of Ethanol in a Putative Roder Biochem Behav, 54:541-546, 1996	nt Model of Tardive D	yskinesia", Pharmaco	,1 I	

			_	
	*	Atty, Docket:	In re Application No.	
Form PTO-1449	•	0264724-0007	09/193,892	
(REV. 8-83)	Patent and Trademark Office		CB CC	
	011 8	Applicant: Fogel		
	ENTAL INFORMATION		9 F	
DISCL	LOSURE STATEMENT (SEP 2 8 2001)		88	
•		Filing Date:	Group: 1€4 😑 🔲	
(Use se	everal sheets if necessary)	November 18, 1998) % D	
	Steingard, "Adjunctive Clonazepam Treatment	of Tie Symptoms in C	hildren with Comorbid	
1	Tic Disorders and ADHD, J. Am. Acad. Child			
$\mathcal{I}_{\mathbf{A}}$	1994	Adolese. Psychiatry,	55.5, Match/April,	
	1994			
	Swartz, "Tardive Psychopathology", Neuropsyc	chobiology, 43:115-119	9, 1995.	
	Tirelli et al., "Differential Effects of Direct and	I Indirect Dopamine A	gonists on the	
	Induction of Gnawing in C57B1/6J Mice", J. P.	harmacol Exp. Ther.,	273:7-15, 1995.	
	Trube et al "Devtromethornhan: Cellular Eff.	ects Reducing Neurons	1 Hyperactivity"	
	Trube, et al., "Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity" Epilepsia. 35:5 S62-S67, 1994			
	Tsai et al "Markers of Glutamatergic Neurott	ransmission and Oxida	tive Stress Associated	
\	Tsai, et al., "Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia", Am J. Psychiatry 155:9, September, 1998.			
	Vale et al., "Amantadine for Dyskinesia Tarda", New Eng. J. Med., 284:673, 1971.			
	Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", Brian Inj. 9:49-53, 1995.			
·	Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed			
	Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive			
	Dyskinesia", Psychol Med, 26:681-688, 1996.			
	Dyskinesia, Fsychol Med, 20.001-000, 1990.			
	Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the			
	Nucleus Basalis Magnocellularis", Eur. J. Phara	macol, 293:267-270, 1	995.	
	Wilde, et al., "Acamprosate", Adis Drug Evaluation, 53:1038-1053, June, 1997.			
Vacca et al "Plasma Magnesium in Chronic Schizonbrenia" Int. Dharmaconsychiat				
	Yassa, et al., "Plasma Magnesium in Chronic Schizophrenia", Int. Pharmacopsychiat. 14:57-64 (1979)			
Ziemann, et al., "Decreased Motor Inhibition in Tourette's Disorder: Evidence From				
Transcranial Magnetic Stimulation", Am J Psychiatry, 154:1277-1284, 1997.				
, i				
	1			
EXAMINER	- / M	DATE CONSIDER	ED 11/5/28	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.